Biotech Values

[DewDiligence]

RMTI—They supposedly are going to announce the launch of their FDA approved drug, Triferric after the bell.

They didn’t—from today’s PR (http://finance.yahoo.com/news/rockwell-medical-reports-second-quarter-200100182.html ):

Since our FDA approval of Triferic, interest from the clinical community in gaining access to the drug has been strong across large and small dialysis organizations. Short-term pilot evaluations are being coordinated among some of the larger groups to establish internal protocol, prior to clinic-wide use. We anticipate these pilot studies will begin in the next few weeks. Once internal protocols are established and working satisfactorily, we expect to see broad-based clinical adoption of Triferic.

Sounds like BS.